GlaxoSmithKline's (GSK) Votrient, which is approved to treat kidney cancer or soft-tissue...


GlaxoSmithKline's (GSK) Votrient, which is approved to treat kidney cancer or soft-tissue sarcoma, extended the time taken for ovarian cancer to worsen in patients by an average of 5.6 months in a Phase III trial. The results suggest that Votrient could be used as a "maintenance" therapy, although an interim analysis found no difference in overall survival rates between the drug and a placebo. The findings were presented at the annual meeting of the American Society of Clinical Oncology. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs